Product Highlights
BÜHLMANN offers a comprehensive gastroenterology testing portfolio designed to support confident clinical decision‑making across inflammatory and functional GI disorders.
Fecal calprotectin and pancreatic elastase are often ordered together to assess GI function
BÜHLMANN’s non‑invasive stool testing solutions support evaluation of intestinal inflammation and pancreatic function from a single sample using clinically established biomarkers. Timely results aid patient stratification and informed clinical decision‑making, while CALEX® sample handling supports consistent, reliable performance in routine GI practice.
BÜHLMANN fCAL® turbo & CALEX® Cap (FDA 510(k) cleared. For in vitro Diagnostic Use.
BÜHLMANN fPELA® turbo is FDA 510(k) Exempt. For in vitro Diagnostic Use.
BUHLMANN product listed above is IVDR compliant.
BÜHLMANN DDW Poster
Connect with Adam at the Poster Session!
Key Findings:
High comparability observed across all BÜHLMANN fCAL assays
Strong clinical alignment with histoendoscopic findings
Findings underscore the importance of detection of active inflammation without compromising sensitivity for specificity
Venue Information
Join us at DDW 2026 at Chicago, IL & Online
Hosted by: Digestive Disease Association (DDW)
When: May 2-5, 2026
Location: McCormick Place
Booth: #2318
